Articles tagged with Thrombosis
Research analyzing 4.184 million genetic data from 23andMe participants found that those with sickle cell trait have a higher risk of venous thromboembolism and pulmonary embolism, yet relatively lower risk of blood clotting overall compared to FVL.
A clinical trial led by Washington University School of Medicine found that two anti-coagulant drugs did not improve outcomes for patients who received vessel-clearing interventions after a blood clot in the brain. The study aimed to test whether adding these medications could prevent further clots, but results showed no benefit.
A randomized trial found that continuing oral anticoagulants after transcatheter aortic valve implantation did not reduce thromboembolic events but increased bleeding risk. The study suggests interrupting OACs may be beneficial for patients undergoing TAVI.
A new textured heart valve implant has been shown to be less likely to cause clotting, improving health outcomes for patients who receive the implant. Certain conditions such as cancer and smoking elevate the risk of blood clots after heart surgery.
A new study by the Cleveland Clinic found that consuming foods with erythritol increases the risk of cardiovascular events such as heart attack and stroke. The artificial sweetener makes platelets more active, which can raise blood clot risks. This research adds to evidence that erythritol may not be as safe as previously thought.
A study by Michigan Medicine found that over- or under-dosing anticoagulants can result in serious health conditions, most often occurring after the initial prescription. The researchers evaluated five years of prescribing data and found that nearly 70% of alerts to off-label dosing occurred during a follow-up visit.
Researchers found that anxiety disorders and depression significantly elevate the risk of incident DVT. Stress-related neural mechanisms may increase DVT risk through heightened activation of stress pathways.
Researchers investigated the effectiveness of systemic thrombolysis for acute portal vein thrombosis (PVT) in liver cirrhosis patients. After a 7-day treatment period, 60% of patients achieved full recanalization of the portal vein, with no significant side effects.
A study investigated current outcomes after revascularization for angiographically confirmed very late stent thrombosis (VLST), revealing a total MACE rate of 35.46%. Left ventricular ejection fraction and peak troponin I at VLST onset were independent predictors of MACE.
A new anticoagulant with on-demand reversible activity has been developed by a team from UNIGE and the University of Sydney. This breakthrough offers a more reliable and easier-to-use option for surgical procedures, reducing the risk of serious bleeding associated with current treatments.
Researchers at Rensselaer Polytechnic Institute have developed a patented process to produce heparin in the lab, offering a consistent and safe supply of the essential medicine. The discovery has the potential to revolutionize the production of heparin, reducing reliance on animal-derived sources and addressing global supply chain issues.
A study found that 2-methylbutyrylcarnitine (2MBC), a gut microbial metabolite, exacerbates thrombosis and is accumulated in COVID-19 patients. Elevated 2MBC levels are associated with increased blood clot risk, suggesting a potential mechanism linking gut microbiota dysbiosis to cardiovascular disease.
Using intravascular imaging to guide stent implantation significantly improves survival and reduces adverse cardiovascular events compared to angiography-guided PCI. The study found a 25% reduction in all-cause death, 45% reduction in cardiac death, and improved outcomes for patients with coronary artery disease.
A study of 352 patients found that endovascular thrombectomy benefits both directly presenting and transferred patients with large ischemic strokes, with better functional outcomes observed in those presenting directly to EVT-capable centers. Prolonged transfers worsened outcomes due to evolving ischemic change.
A randomized clinical trial of 1,680 patients with acute ischemic stroke due to large-vessel occlusion found no significant improvement in disability with adjunctive methylprednisolone. The study suggests that methylprednisolone may not be effective as an adjunct therapy after endovascular thrombectomy for this patient population.
Intravenous thrombolysis (IVT) plus thrombectomy demonstrates significant benefits over thrombectomy alone when administered within a short timeframe after symptom onset. This study, based on individual participant data from six randomized clinical trials, found IVT before thrombectomy to be time-dependent and statistically significant.
The study analyzed over 1 million stroke patients and found that the Target: Stroke quality initiative led to increased thrombolysis frequency, timeliness, and improved outcomes across all racial and ethnic groups. However, disparities persisted, highlighting the need for further interventions.
A recent study published in Hepatology has investigated the connection between platelet function and complications in patients with cirrhosis. The researchers found that decreased platelet activation predicts hepatic decompensation and mortality, highlighting the importance of personalized therapeutic approaches.
Researchers found that adding blood thinners to clot-busting medications for ischemic strokes did not improve physical function at 90 days post-stroke. The study, MOST, enrolled 514 patients and analyzed the effectiveness of two blood-thinning medications.
Korea University researchers found that perioperative radiotherapy significantly improves survival rates among HCC patients at high risk of recurrence. The study suggests that radiotherapy can reduce recurrence and improve survival in these patients, providing a significant adjuvant treatment option.
A large study of 432,000 cancer patients who underwent major surgery found an increased rate of venous thromboembolism associated with cancer surgery. The risk persisted for about two to four months postoperatively and varied between cancer types.
A systematic review of 95 studies found that 3D camera system estimates, patient self-estimates, and the Lorenz method are accurate for estimating adult body weight. However, no method is foolproof, and alternative strategies should be available when patients are unable to provide an estimate.
Researchers found rivaroxaban associated with nearly 40 bleeding events per 100 patients over a year, while apixaban had similar bleeding events as warfarin but more major bleeds. Apixaban also showed lower mortality rates compared to the other medications.
A Brazilian study found that damage to small blood vessels in the lungs causes severe COVID-19. The researchers observed high prevalence of microscopic blood clots in lung endothelial cells, which led to organ damage and ischemic tissue injury.
Researchers at Temple University Health System report that the BASHIR Endovascular Catheter reduces blockages in lung arteries and correlates with improved right ventricle function, suggesting better survival outcomes. The catheter also shows significantly lower bleeding rates compared to other devices.
A randomized clinical trial found that excluding aspirin from the antithrombotic regimen in LVAD patients improved adverse event rates by a significant reduction in non-surgical bleeding. The study results suggest that an aspirin-free regimen is safe and may improve longevity, morbidity, and quality of life for these patients.
A randomized clinical trial found that avoiding aspirin as part of an antithrombotic regimen reduces bleeding events without increasing thromboembolism risk in patients with advanced heart failure treated with left ventricular assist devices. The study suggests that aspirin avoidance may be a viable option for these patients.
A new study suggests that hormonal contraceptives significantly increase the risk of blood clots, but stopping their use can normalize this risk within two to four weeks. After stopping birth control, clotting markers return to normal levels within one to two weeks and nearly completely by week 12.
Scientists at the University of Birmingham have identified a mechanism that led to some patients experiencing deadly clotting following Covid-19 vaccination. The team found that Platelet factor 4 (PF4) activates the c-Mpl-Jak2 pathway in platelets, triggering clot formation.
Researchers at the University of Birmingham have created binding molecules to make platelets clump together, enabling validated clinical assays and research tools for studying platelet activation. The 'nanobody' technology shows promise for developing therapeutics for blood and thrombotic disorders.
A large-scale clinical study confirms the validity of the Vienna Prediction Model in identifying low-risk patients with venous thromboembolism who may not require long-term blood thinning. The model's accuracy was found to be 5.2% after one year for patients with a low relapse risk, but adjustments were made to correct imprecision.
A large study of 74,471 patients found that those who quit smoking after percutaneous coronary intervention (PCI) have comparable rates of heart attacks, strokes, and deaths to non-smokers. However, heavy smokers showed no improvement in cardiovascular outcomes.
A new study from Uppsala University has found that women with a high genetic predisposition for blood clots are six times more likely to develop a blood clot during the first two years of using contraceptive pills. This knowledge could be used to identify women at risk and counsel them on alternative methods of contraception.
A Geisinger-led study found that knowing the genetic cause of high cholesterol increases heart disease risk more than having high cholesterol levels alone. The study used UK Biobank data and observed distinct differences in heart disease rates among participants with different genetic causes.
A study found that ultrasound scans performed by emergency physicians can nearly halve the time patients spend in emergency departments. This technology, known as point-of-care ultrasound (POCUS), enables faster diagnoses and treatment for suspected deep vein thrombosis (DVT).
A study published in NPJ Aging reveals that COVID-19 exacerbates production of auto-antibodies associated with blood clotting disorders and aging. Researchers found that severe COVID-19 cases display a significant age-related increase in auto-antibodies, which can lead to tissue injury and organ damage.
Researchers are developing a new treatment for ischemic stroke by targeting the prostaglandin receptor EP2, which could have a wider therapeutic window and improve behavioral outcomes. The potential new treatment has the potential to reduce inflammation and provide protection for neurons after an ischemic stroke.
Women who use non-steroidal anti-inflammatory painkillers alongside hormonal contraception may be at a small increased risk of developing venous thromboembolism. High-risk hormonal contraception and NSAIDs like diclofenac are linked to higher blood clot risks.
A Michigan Medicine study found that pulmonary embolism death rates remained unchanged over the past decade, with higher mortality rates among men, Black patients, and those from rural areas. The study analyzed over 100,000 deaths related to pulmonary embolism between 2006 and 2019.
Researchers have discovered a link between adenovirus infection and an anti-platelet factor 4 disorder, which can cause severe thrombocytopenia. The condition is rare and potentially fatal, and has been reported in patients with viral symptoms and no exposure to heparin or vaccines.
A team of investigators developed a novel technology to diagnose immunothrombosis, a major cause of morbidity among patients with sepsis or severe COVID-19. By measuring thrombin activity through breath gas, they can provide unprecedented knowledge of key enzymatic activity anywhere in the body.
A new strategy targeting hospital procedures and community education led to a significant increase in thrombolysis rates, reducing post-stroke disability. The program, known as Stroke Ready, improved equity in stroke treatment for Black individuals who experience more strokes at younger ages.
The American College of Chest Physicians (CHEST) has released a new clinical guideline for managing antithrombotic therapy in patients with COVID-19-related arterial thrombosis and thromboembolism. The guideline provides evidence-based recommendations to improve risk-evaluation and treatment course.
A large-scale study found that patients with pulmonary embolism treated with mechanical thrombectomy showed significant improvement in symptoms, quality of life, and cardiac functions. Long-term data also suggested low mortality rates following treatment with the FlowTriever System.
The Society for Cardiovascular Angiography & Interventions (SCAI) has released an expert consensus on the management of in-stent restenosis and stent thrombosis. The guidelines emphasize frequent use of intracoronary imaging to determine the precise etiology and guide selection of treatment options.
A recent study found that COVID-19 infection can lead to increased infarct growth and ongoing tissue consumption even after successful reperfusion through angiography. This suggests a potentially aggressive clinical course for patients with COVID-19 and large-vessel occlusion acute ischemic stroke.
A global clinical trial found that bioresorbable vascular scaffolds (BVS) are nearly as safe and effective as conventional metal stents in treating coronary artery disease. The study, led by a researcher from the Mount Sinai Hospital, showed improved outcomes for patients when properly implanted.
Researchers found that immune-modulating cells may slow the expansion of bulges in the aorta by creating a less-inflammatory environment. A second study discovered evidence that a COVID-19 infection promotes the enlargement of abdominal aortic aneurysms, which are extremely dangerous and potentially fatal if they rupture.
A new study by Arianna Anticoagulation Foundation suggests that patients with COVID-19-associated venous thromboembolism may not require prolonged anticoagulant therapy, with a limited duration of 3-6 months being adequate for most patients. The START2-COVID-VTE observational study found low rates of thrombotic recurrences in both groups.
A new study reveals delayed diagnosis of HoFH leads to premature cardiovascular disease, highlighting the need for increased lipid screening and aggressive treatment. Despite available therapies, most patients require further lipid-lowering treatments.
Researchers have developed a 'vein-on-a-chip' device that mimics the human vein, eliminating the need for animal models in some studies. The device, which includes structures called valves and endothelial cells, allows scientists to study mechanisms of blood clot formation in a realistic manner.
A long-term analysis reveals that approximately one-third of CTEPH patients also have left heart disease, which can worsen breathing symptoms and requires more comprehensive diagnostic approaches. The study suggests that treatment options for both conditions may overlap, necessitating further research to find effective therapies.
Researchers at UBC and the University of Michigan have discovered a new compound, MPI 8, that prevents blood clots without increasing bleeding risk. This breakthrough could lead to improved treatment options for patients affected by blood clots.
Researchers found that correctly occluded left atrial appendages minimized left atrial flow stasis and thrombogenicity using 4D flow MRI and 3D phantoms. The study provides a clinical goal for the procedure in patients with atrial fibrillation.
A study by an international research team has found a mechanism that occurs in brown bears and paraplegics, preventing the formation of blood clots. The discovery could lead to new treatments for venous thromboembolism, a life-threatening condition.
Research discovers that reduced levels of Hsp47 protein can prevent blood clots in humans, pigs, and bears, even when immobile for extended periods. The study's findings could lead to new medicines for people with inherited blood clotting disorders.
Researchers found decreased lung injury, coughing up blood, and mortality rates after balloon pulmonary angioplasty between 2013 and 2022. The minimally invasive procedure is now considered a safer option for inoperable CTEPH patients.
A new study has deciphered a central regulatory mechanism of fibrin formation, proposing therapeutic approaches. Glycoprotein V controls thrombin activity and limits fibrin formation.
A study of 398,000 COVID-19 patients found the absolute risk of venous thromboembolism to be low overall. Patient-level factors associated with higher risk may help identify subsets of patients who could benefit from more intensive surveillance or preventive strategies.
Research suggests that withholding gender-affirming hormone therapy from transgender individuals may have negative mental and physical effects. A new study provides comprehensive guidance for assessing, managing, and treating venous thromboembolism in transgender patients receiving feminizing hormone therapy.